These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 20027114)

  • 21. Guidelines for breast and ovarian cancer genetic counseling referral: adoption and implementation in HMOs.
    Mouchawar J; Valentine Goins K; Somkin C; Puleo E; Hensley Alford S; Geiger AM; Taplin S; Gilbert J; Weinmann S; Zapka J
    Genet Med; 2003; 5(6):444-50. PubMed ID: 14614396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recognizing BRCA gene mutation risk subsequent to breast cancer diagnosis in southwestern Ontario.
    Vanstone M; Chow W; Lester L; Ainsworth P; Nisker J; Brackstone M
    Can Fam Physician; 2012 May; 58(5):e258-66. PubMed ID: 22734169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.
    Shulman LP
    Obstet Gynecol Clin North Am; 2010 Mar; 37(1):109-33, Table of Contents. PubMed ID: 20494261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparison of hereditary breast and ovarian cancer syndrome and sporadic ovarian cancer in ovarian cancer BRCA mutations].
    Duan RR; Sun LX; Zhao HW
    Zhonghua Fu Chan Ke Za Zhi; 2021 Nov; 56(11):788-795. PubMed ID: 34823292
    [No Abstract]   [Full Text] [Related]  

  • 25. BRCA1/2 testing in hereditary breast and ovarian cancer families II: impact on relationships.
    McInerney-Leo A; Biesecker BB; Hadley DW; Kase RG; Giambarresi TR; Johnson E; Lerman C; Struewing JP
    Am J Med Genet A; 2005 Mar; 133A(2):165-9. PubMed ID: 15633195
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implementing a screening tool for identifying patients at risk for hereditary breast and ovarian cancer: a statewide initiative.
    Brannon Traxler L; Martin ML; Kerber AS; Bellcross CA; Crane BE; Green V; Matthews R; Paris NM; Gabram SG
    Ann Surg Oncol; 2014 Oct; 21(10):3342-7. PubMed ID: 25047474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Study protocol: a cluster randomized controlled trial of web-based decision support tools for increasing BRCA1/2 genetic counseling referral in primary care.
    Silverman TB; Vanegas A; Marte A; Mata J; Sin M; Ramirez JCR; Tsai WY; Crew KD; Kukafka R
    BMC Health Serv Res; 2018 Aug; 18(1):633. PubMed ID: 30103738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identifying Women at Risk for Hereditary Breast and Ovarian Cancer Syndrome Utilizing Breast Care Nurse Navigation at Mammography and Imaging Centers.
    Appel SJ; Cleiment RJ
    J Natl Black Nurses Assoc; 2015 Dec; 26(2):17-26. PubMed ID: 27045154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An exploration of the communication preferences regarding genetic testing in individuals from families with identified breast/ovarian cancer mutations.
    Ratnayake P; Wakefield CE; Meiser B; Suthers G; Price MA; Duffy J; ; Tucker K
    Fam Cancer; 2011 Mar; 10(1):97-105. PubMed ID: 20878485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Impact of Angelina Jolie (AJ)'s Story on Genetic Referral and Testing at an Academic Cancer Centre in Canada.
    Raphael J; Verma S; Hewitt P; Eisen A
    J Genet Couns; 2016 Dec; 25(6):1309-1316. PubMed ID: 27228984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Present status and tasks for genetic testing and risk-reducing surgery in patients with hereditary breast and ovarian cancer].
    Arai M; Taki K; Iwase H; Takizawa K; Nishimura S; Iwase T
    Gan To Kagaku Ryoho; 2012 Apr; 39(4):525-31. PubMed ID: 22504676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complete BRCA mutation screening in breast and ovarian cancer predisposition families from a North-Eastern Romanian population.
    Negura L; Uhrhammer N; Negura A; Artenie V; Carasevici E; Bignon YJ
    Fam Cancer; 2010 Dec; 9(4):519-23. PubMed ID: 20567915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Why Is Cancer Genetic Counseling Underutilized by Women Identified as at Risk for Hereditary Breast Cancer? Patient Perceptions of Barriers Following a Referral Letter.
    Kne A; Zierhut H; Baldinger S; Swenson KK; Mink P; Veach PM; Tsai ML
    J Genet Couns; 2017 Aug; 26(4):697-715. PubMed ID: 27826805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population.
    Bellcross CA; Lemke AA; Pape LS; Tess AL; Meisner LT
    Genet Med; 2009 Nov; 11(11):783-9. PubMed ID: 19752737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
    Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
    Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The counselees' self-reported request for psychological help in genetic counseling for hereditary breast/ovarian cancer: not only psychopathology matters.
    Vos J; van Asperen CJ; Oosterwijk JC; Menko FH; Collee MJ; Gomez Garcia E; Tibben A
    Psychooncology; 2013 Apr; 22(4):902-10. PubMed ID: 22740372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hereditary breast/ovarian cancer syndrome: a primer for obstetricians/gynecologists.
    Meaney-Delman D; Bellcross CA
    Obstet Gynecol Clin North Am; 2013 Sep; 40(3):475-512. PubMed ID: 24021253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests.
    Pujol P; Lyonnet DS; Frebourg T; Blin J; Picot MC; Lasset C; Dugast C; Berthet P; de Paillerets BB; Sobol H; Grandjouan S; Soubrier F; Buecher B; Guimbaud R; Lidereau R; Jonveaux P; Houdayer C; Giraud S; Olschwang S; Nogue E; Galibert V; Bara C; Nowak F; Khayat D; Nogues C
    Breast Cancer Res Treat; 2013 Aug; 141(1):135-44. PubMed ID: 23974829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of decision aids for female BRCA1 and BRCA2 mutation carriers: a systematic review.
    Krassuski L; Vennedey V; Stock S; Kautz-Freimuth S
    BMC Med Inform Decis Mak; 2019 Aug; 19(1):154. PubMed ID: 31370837
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system.
    McCuaig JM; Care M; Ferguson SE; Kim RH; Stockley TL; Metcalfe KA
    Gynecol Oncol; 2020 Sep; 158(3):747-753. PubMed ID: 32674931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.